Ident. | Authors (with country if any) | Title |
---|
000103 (2011) |
Yoichiro Kikuchi [Japon] ; Takao Yasuhara [Japon] ; Takashi Agari [Japon] ; Akihiko Kondo [Japon] ; Satoshi Kuramoto [Japon] ; Masahiro Kameda [Japon] ; Tomohito Kadota [Japon] ; Tanefumi Baba [Japon] ; Naoki Tajiri [Japon] ; Feifei Wang [Japon] ; Judith T. Tayra [Japon] ; Hanbai Liang [Japon] ; Yasuyuki Miyoshi [Japon] ; Cesario V. Borlongan [États-Unis] ; Isao Date [Japon] | Urinary 8‐OHdG elevations in a partial lesion rat model of parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion |
000114 (2011) |
Mildred D. Gottwald [États-Unis] ; Michael J. Aminoff [États-Unis] | Therapies for dopaminergic‐induced dyskinesias in parkinson disease |
000156 (2011) |
Michael A. Schwarzschild [États-Unis] ; Kenneth Marek [États-Unis] ; Shirley Eberly [États-Unis] ; David Oakes [États-Unis] ; Ira Shoulson [États-Unis] ; Danna Jennings [États-Unis] ; John Seibyl [États-Unis] ; Alberto Ascherio [États-Unis] | Serum urate and probability of dopaminergic deficit in early “Parkinson's disease” |
000186 (2011) |
Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada] | Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts |
000192 (2011) |
Susanne Nikolaus [Allemagne] ; Rolf Larisch [Allemagne] ; Henning Vosberg [Allemagne] ; Markus Beu [Allemagne] ; Andreas Wirrwar [Allemagne] ; Christina Antke [Allemagne] ; Konstantin Kley [Allemagne] ; Maria Angelica De Souza Silva [Allemagne] ; Joseph P. Huston [Allemagne] ; Hans-Wilhelm Müller [Allemagne] | Pharmacological challenge and synaptic response – assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET) |
000225 (2011) |
Ari E. Berman [États-Unis] ; Wai Yee Chan [États-Unis] ; Angela M. Brennan [États-Unis] ; Reno C. Reyes [États-Unis] ; Brittany L. Adler [États-Unis] ; Sang Won Suh [États-Unis] ; Tiina M. Kauppinen [États-Unis] ; Ylva Edling [États-Unis] ; Raymond A. Swanson [États-Unis] | N‐acetylcysteine prevents loss of dopaminergic neurons in the EAAC1−/− mouse |
000265 (2011) |
James A. Miller [États-Unis] ; Briana R. Trout [États-Unis] ; Kelly A. Sullivan [États-Unis] ; Russell A. Bialecki [États-Unis] ; Ruth A. Roberts [Royaume-Uni] ; Ronald B. Tjalkens [États-Unis] | Low‐dose 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine causes inflammatory activation of astrocytes in nuclear factor‐κB reporter mice prior to loss of dopaminergic neurons |
000284 (2011) |
Maria Papathanou [Suède] ; Sarah Rose [Royaume-Uni] ; Andrew Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats |
000338 (2011) |
Alberto J. Espay [États-Unis] ; Joe P. Giuffrida [États-Unis] ; Robert Chen [Canada] ; Megan Payne [États-Unis] ; Filomena Mazzella [Canada] ; Emily Dunn [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Andrew P. Duker [États-Unis] ; Alok Sahay [États-Unis] ; Sang Jin Kim [Canada] ; Fredy J. Revilla [États-Unis] ; Dustin A. Heldman [États-Unis] | Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease |
000519 (2010) |
Y. K. Kim ; I-Y. Yoon ; J-M. Kim [Corée du Sud] ; S-H. Jeong ; K. W. Kim ; Y-K. Shin ; B. S. Kim ; S. E. Kim | The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder |
000680 (2010) |
Shona Pfeiffer [Irlande (pays)] ; David Mclaughlin [Irlande (pays)] | In vitro differentiation of human amniotic fluid‐derived cells: Augmentation towards a neuronal dopaminergic phenotype |
000717 (2010) |
P. O. Valko ; D. Waldvogel ; M. Weller ; C. L. Bassetti [Suisse] ; U. Held ; C. R. Baumann | Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment |
000731 (2010) |
Noriyuki Yamamoto [Japon] ; Yasuhiko Izumi [Japon] ; Takaaki Matsuo [Japon] ; Seiko Wakita [Japon] ; Toshiaki Kume [Japon] ; Yuki Takada-Takatori [Japon] ; Hideyuki Sawada [Japon] ; Akinori Akaike [Japon] | Elevation of heme oxygenase‐1 by proteasome inhibition affords dopaminergic neuroprotection |
000740 (2010) |
Francesco E. Pontieri [Italie] ; Carlo Colosimo [Italie] | Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease |
000741 (2010) |
David Devos [France] ; L. Defebvre [France] ; R. Bordet [France] | Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease |
000770 (2010) |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward |
000784 (2010) |
K. Ishibashi [Japon] ; K. Kanemaru [Japon] ; Y. Saito [Japon] ; S. Murayama [Japon] ; K. Oda [Japon] ; K. Ishiwata [Japon] ; H. Mizusawa [Japon] ; K. Ishii [Japon] | Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease |
000812 (2010) |
Celine Perier [Espagne] ; Jordi Bové [Espagne] ; Benjamin Dehay [Espagne] ; Vernice Jackson-Lewis [États-Unis] ; Peter S. Rabinovitch [États-Unis] ; Serge Przedborski [États-Unis] ; Miquel Vila [Espagne] | Apoptosis‐inducing factor deficiency sensitizes dopaminergic neurons to parkinsonian neurotoxins |
000815 (2010) |
H. C. Yu ; S. F. Feng ; P. L. Chao ; A. M. Y. Lin [Taïwan] | Anti‐inflammatory effects of pioglitazone on iron‐induced oxidative injury in the nigrostriatal dopaminergic system |
000951 (2009) |
Michaela Hahn [Allemagne] ; Marco Timmer [Allemagne] ; Guido Nikkhah [Allemagne] | Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease |
000954 (2009) |
David Weise [Allemagne] ; Reinhard Lorenz [Allemagne] ; Mira Schliesser [Allemagne] ; Andreas Schirbel [Allemagne] ; Karlheinz Reiners [Allemagne] ; Joseph Classen [Allemagne] | Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease |
000958 (2009) |
Matthias Elstner [Allemagne] ; Christopher M. Morris [Royaume-Uni] ; Katharina Heim [Allemagne] ; Peter Lichtner [Allemagne] ; Andreas Bender [Allemagne] ; Divya Mehta [Allemagne] ; Claudia Schulte [Allemagne] ; Manu Sharma [Allemagne] ; Gavin Hudson [Royaume-Uni] ; Stefano Goldwurm [Italie] ; Alessandro Giovanetti [Italie] ; Massimo Zeviani [Italie] ; David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; Robert H. Perry [Royaume-Uni] ; E. Jaros [Royaume-Uni] ; Rejko Krüger [Allemagne] ; H. Rich Wichmann [Allemagne] ; Stefan Schreiber [Allemagne] ; Harry Campbell [Royaume-Uni] ; James F. Wilson [Royaume-Uni] ; Alan F. Wright [Royaume-Uni] ; Malcolm Dunlop [Royaume-Uni] ; Giorgio Pistis [Italie] ; Daniela Toniolo [Italie] ; Patrick F. Chinnery [Royaume-Uni] ; Thomas Gasser [Allemagne] ; Thomas Klopstock [Allemagne] ; Thomas Meitinger [Allemagne] ; Holger Prokisch [Allemagne] ; Douglass M. Turnbull [Royaume-Uni] | Single‐cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene |
000970 (2009) |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation |
000A14 (2009) |
Hiroki Takeuchi [Japon] ; Takashi Yanagida [Japon] ; Masatoshi Inden [Japon] ; Kazuyuki Takata [Japon] ; Yoshihisa Kitamura [Japon] ; Kentaro Yamakawa [Japon] ; Hideyuki Sawada [Japon] ; Yasuhiko Izumi [Japon] ; Noriyuki Yamamoto [Japon] ; Takeshi Kihara [Japon] ; Kengo Uemura [Japon] ; Haruhisa Inoue [Japon] ; Takashi Taniguchi [Japon] ; Akinori Akaike [Japon] ; Ryosuke Takahashi [Japon] ; Shun Shimohama [Japon] | Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models |
000A18 (2009) |
You-Joung Kim [Corée du Sud] ; Hyun-Jung Park [Corée du Sud] ; Gwang Lee [Corée du Sud] ; Oh Young Bang [Corée du Sud] ; Young Hwan Ahn [Corée du Sud] ; Eunhye Joe [Corée du Sud] ; Hyun Ok Kim [Corée du Sud] ; Phil Hyu Lee [Corée du Sud] | Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti‐inflammatory action |
000A73 (2009) |
Na K. Kim [Corée du Sud] ; Byung H. Choi [Corée du Sud] ; Xian Huang [Corée du Sud] ; Brian J. Snyder [Canada] ; Shefqat Bukhari [Canada] ; Tae-Ho Kong [Corée du Sud] ; Hyeonseon Park [Corée du Sud] ; Hyung C. Park [Corée du Sud] ; So R. Park [Corée du Sud] ; Yoon Ha [Corée du Sud] | Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model |
000B08 (2009) |
C. G. Bachmann ; A. Zapf [Allemagne] ; E. Brunner [Allemagne] ; C. Trenkwalder | Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias |
000B09 (2009) |
C. Warren Olanow [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; Anthony E. Lang [Canada] ; Jose A. Obeso [Espagne] | Dopaminergic transplantation for parkinson's disease: Current status and future prospects |
000B43 (2009) |
A H Evans [Australie, Royaume-Uni] ; A D Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease |
000B66 (2009) |
Koen Bossers [Pays-Bas] ; Gideon Meerhoff ; Rawien Balesar [Pays-Bas] ; Jeroen W. Van Dongen [Pays-Bas] ; Chris G. Kruse [Pays-Bas] ; Dick F. Swaab [Pays-Bas] ; Joost Verhaagen | Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death |
000D06 (2008) |
Andreas Gebhardt [Suisse] ; Tim Vanbellingen [Suisse] ; Fabio Baronti [Suisse] ; Bernd Kersten [Suisse] ; Stephan Bohlhalter [Suisse] | Poor dopaminergic response of impaired dexterity in Parkinson's disease: Bradykinesia or limb kinetic apraxia? |
000E35 (2008) |
M. Steiger [Royaume-Uni] | Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease |
000E59 (2008) |
Anna R. Carta [Italie] ; Frau Lucia [Italie] ; Pinna Annalisa [Italie] ; Pontis Silvia [Italie] ; Simola Nicola [Italie] ; Schintu Nicoletta [Italie] ; Morelli Micaela [Italie] | Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6‐OHDA lesioned rat |
000F26 (2007) |
Risa Sakai [Japon] ; Yoshifumi Irie [Japon] ; Takeshi Murata [Japon] ; Atsushi Ishige [Japon] ; Naoko Anjiki [Japon] ; Kenji Watanabe [Japon] | Toki‐to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice |
000F67 (2007) |
Thomas Eckert [États-Unis, Allemagne] ; Andrew Feigin [États-Unis] ; Daniel E. Lewis [États-Unis] ; Vijay Dhawan [États-Unis] ; Steven Frucht [États-Unis] ; David Eidelberg [États-Unis] | Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging |
000F72 (2007) |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
000F75 (2007) |
I. Rite [Espagne] ; S. Argüelles [Espagne] ; J. L. Venero [Espagne] ; S. García-Rodriguez [Espagne] ; A. Ayala [Espagne] ; J. Cano [Espagne] ; A. Machado [Espagne] | Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration |
000F78 (2007) |
Yuji Nagai [Japon] ; Shigeru Obayashi [Japon] ; Kiyoshi Ando [Japon] ; Motoki Inaji [Japon] ; Jun Maeda [Japon] ; Takashi Okauchi [Japon] ; Hiroshi Ito [Japon] ; Tetsuya Suhara [Japon] | Progressive changes of pre‐ and post‐synaptic dopaminergic biomarkers in conscious MPTP‐treated cynomolgus monkeys measured by positronemission tomography |
001004 (2007) |
Hyun Jung Park [Corée du Sud] ; Phil Hyu Lee [Corée du Sud] ; Young Whan Ahn [Corée du Sud] ; Yun Jung Choi [Corée du Sud] ; Gwang Lee [Corée du Sud] ; Da-Yong Lee [Corée du Sud] ; Eun S. Chung [Corée du Sud] ; Byung Kwan Jin [Corée du Sud] | Neuroprotective effect of nicotine on dopaminergic neurons by anti‐inflammatory action |
001011 (2007) |
Wei Zhang [États-Unis, République populaire de Chine] ; Shannon Dallas [États-Unis] ; Dan Zhang [États-Unis] ; Jian-Ping Guo [Canada] ; Hao Pang [États-Unis] ; Belinda Wilson [États-Unis] ; David S. Miller [États-Unis] ; Biao Chen [République populaire de Chine] ; Wanqin Zhang [République populaire de Chine] ; Patrick L. Mcgeer [Canada] ; Jau-Shyong Hong [États-Unis] ; Jing Zhang [États-Unis] | Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein |
001022 (2007) |
Martin Köllensperger [Autriche] ; Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy |
001035 (2007) |
Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] | Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study |
001040 (2007) |
Emilie Lacombe ; Carole Carcenac ; Sabrina Boulet ; Claude Feuerstein [France] ; Anne Bertrand ; Annie Poupard ; Marc Savasta [France] | High‐frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l‐3,4‐dihydroxyphenylalanine in dopaminergic denervated rats |
001068 (2007) |
Quincy J. Almeida [Canada] ; James S. Frank [Canada] ; Eric A. Roy [Canada] ; Aftab E. Patla [Canada] ; Mandar S. Jog [Canada] | Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease |
001088 (2007) |
John G. Nutt [États-Unis] | Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? |
001128 (2007) |
Masaki Wakamatsu [Japon] ; Aiko Ishii [Japon] ; Yuriko Ukai [Japon] ; Junko Sakagami [Japon] ; Shingo Iwata [Japon] ; Mieko Ono [Japon] ; Kayo Matsumoto [Japon] ; Atsushi Nakamura [Japon] ; Norihiro Tada [Japon] ; Kazuto Kobayashi [Japon] ; Takeshi Iwatsubo [Japon] ; Makoto Yoshimoto [Japon] | Accumulation of phosphorylated α‐synuclein in dopaminergic neurons of transgenic mice that express human α‐synuclein |
001219 (2006) |
Patrick Mclaughlin [États-Unis] ; Yong Zhou [États-Unis] ; Tracy Ma [États-Unis] ; Jun Liu [États-Unis] ; Wei Zhang [États-Unis] ; Jau-Shyong Hong [États-Unis] ; Monika Kovacs [États-Unis] ; Jing Zhang [États-Unis] | Proteomic analysis of microglial contribution to mouse strain–dependent dopaminergic neurotoxicity |
001261 (2006) |
Arthi Kanthasamy [États-Unis] ; V. Anantharam [États-Unis] ; Syed F. Ali [États-Unis] ; A. G. Kanthasamy [États-Unis] | Methamphetamine Induces Autophagy and Apoptosis in a Mesencephalic Dopaminergic Neuronal Culture Model |
001275 (2006) |
Antti J. V N Nen [Finlande] ; Pekka Rauhala [Finlande] ; Raimo K. Tuominen [Finlande] ; P Ivi Liesi [Finlande, États-Unis] | KDI tripeptide of γ1 laminin protects rat dopaminergic neurons from 6‐OHDA induced toxicity |
001406 (2005) |
Mahmoud M. Iravani [Royaume-Uni] ; Clement C. M. Leung [Royaume-Uni] ; Mona Sadeghian [Royaume-Uni] ; Claire O. Haddon [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation |
001416 (2005) |
Pedro Barroso-Chinea [Espagne] ; Ignacio Cruz-Muros [Espagne] ; María S. Aymerich [Espagne] ; Manuel Rodríguez-Díaz [Espagne] ; Domingo Afonso-Oramas [Espagne] ; José L. Lanciego [Espagne] ; Tomás González-Hernández [Espagne] | Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells |